Autopsy report · NCT03005639

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

“Sponsor has decided to close study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Inova Health Care Services

Sponsor type

University, hospital or other

Conditions

Stage IIIB-C Melanoma

Interventions

Vemurafenib and Cobimetinib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
  “Study sponsor decided to close study.” (97% match in meaning)
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
  “Sponsor Decision to close study” (95% match in meaning)
• L-Menthol Injection as a Novel Technique During Colonoscopy
  “Sponsor/Investigator has decided to close out the study” (89% match in meaning)
• Feasibility Study of the transShield Embolic Protection System
  “Study Sponsor closing study due to financial circumstances.” (85% match in meaning)
• Evaluation of Tissue Oxygen Levels During Breast Reconstruction With a New Surgical Device
  “Sponsor decision to end study.” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.